Strides Pharma Science Limited — Investor Meet, 07-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Strides Pharma will attend an investor conference on August 12, discussing Q1 FY26 financial results. The company reported a solid quarter: Revenue at ₹1,119.7 Cr (+6.2% YoY), Gross Margin at 60.3% (+300bps), and EBITDA at 19.5% (+150bps). Operational PAT surged to ₹114.0 Cr (+80.6% YoY), a record. Management highlighted strong operating leverage and a focus on cost management. US market outlook targets ~$400 million by FY27-28; 60 dormant ANDAs are key. Net Debt reduced to ₹1,495.8 Cr. The company is confident about future growth driven by R&D and disciplined execution.